Abstract: A BLyS antibody, preparation method therefor and application thereof, the BLyS antibody comprising one or more of CDR1, CDR2 and CDR3 of a heavy chain variable region of the BLyS antibody, and/or one or more of CDR1, CDR2 and CDR3 of a light chain variable region of the BLyS antibody. An amino acid sequence of the antibody is shown in a sequence listing. The BLyS antibody has a high affinity, and may observably and effectively seal a BLyS protein at a protein level and a cell level, and prevent the BLyS protein from binding to a receptor. The BLyS antibody lacks a cross-reaction with homologous protein antigens such as human APRIL, and enjoys good biological activity. The BLyS antibody may inhibit the proliferation of human BLyS-induced mouse B cells and may therefore be used for preparing a drug for preventing or treating diseases associated with BLyS expression or dysfunction.

Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.

Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: A bispecific monoclonal antibody is described which comprises two moieties, one of which comprises an antigen-binding region which is specific for either the IL-12R?1 or the IL-12R?2 subunit of an IL-12 receptor, and the other of which comprises an antigen-binding region which is specific for either the IL-18R or the AcPL subunit of an IL-18 receptor.

Abstract: A soluble, heterodimeric interleukin 18 (IL-18) receptor molecule is described which comprises two subunits, one of which comprises an extracelluar domain, or a fragment thereof, of IL-18R, and the other of which comprises an extracelluar domain, or a fragment thereof, of AcPL. Preferably, the soluble, heterodimeric receptor binds to IL-18 with higher affinity than does either IL-18R or AcPL alone.

Abstract: A bispecific monoclonal antibody is described which comprises two moieties, one of which comprises an antigen-binding region which is specific for either the IL-12R&bgr;1 or the IL-12R&bgr;2 subunit of an IL-12 receptor, and the other of which comprises an antigen-binding region which is specific for either the IL-18R or the AcPL subunit of an IL-18 receptor.